MOG (35-55): Gold-Standard Peptide for Experimental Autoimmune Encephalomyelitis Induction

Executive Summary: MOG (35-55) is a truncated peptide (amino acids 35–55) derived from human myelin oligodendrocyte glycoprotein, used extensively to induce EAE, a well-characterized animal model for multiple sclerosis (MS) (Xu et al., 2025). The peptide elicits robust T and B cell-mediated immune responses, causing demyelinating lesions that recapitulate MS pathology in mice. MOG (35-55) administration with complete Freund’s adjuvant (CFA) leads to dose-dependent neuroinflammation and weight loss, with reproducible induction of relapsing-remitting disease phenotypes (MHC-Class-II-Antigen, 2024). In vitro, the peptide modulates oxidative stress and extracellular matrix remodeling via increased NADPH oxidase and MMP-9 activity. APExBIO supplies validated MOG (35-55) (SKU: A8306), supporting mechanistic and translational autoimmune research (APExBIO).

Biological Rationale

MOG (35-55) is derived from the extracellular domain of human myelin oligodendrocyte glycoprotein (MOG), an immunoglobulin superfamily member expressed on the outermost surface of CNS myelin (Xu et al., 2025). The 21-amino-acid peptide enables selective activation of autoreactive lymphocytes, mimicking the immunopathogenesis of MS. Its epitope is recognized by MHC class II molecules in susceptible mouse strains, triggering a cascade that includes T cell priming, B cell activation, and antibody production. The use of MOG (35-55) in combination with CFA and pertussis toxin recapitulates key features of human MS, including demyelination, neuroinflammation, and relapsing-remitting disease courses (MHC-Class-II-Antigen, 2024). Compared to full-length MOG or alternative peptides, this fragment offers high reproducibility and disease penetrance, making it the established inducer for EAE (Myelin-Basic-Protein, 2024).

Mechanism of Action of MOG (35-55)

Upon subcutaneous administration with CFA, MOG (35-55) is taken up by antigen-presenting cells, presented via MHC II, and activates CD4+ T cells. This activation leads to clonal expansion of Th1 and Th17 cells, secretion of pro-inflammatory cytokines (e.g., IFN-γ, IL-17), and infiltration of immune cells into the CNS. B cells generate anti-MOG autoantibodies, contributing to demyelination through complement activation and antibody-dependent cytotoxicity. In vitro, MOG (35-55) increases NADPH oxidase activity and MMP-9 levels, promoting oxidative stress and matrix remodeling—key processes in neuroinflammatory damage (Xu et al., 2025). The peptide is soluble in water (≥32.25 mg/mL) and DMSO (≥86 mg/mL), but insoluble in ethanol; proper dissolution enhances reproducibility (APExBIO). Recent mechanistic insights highlight the role of type I interferon signaling and PARP7-mediated STAT1/STAT2 regulation in EAE severity, with MOG (35-55) providing a tractable system for these studies (IGH-1, 2024).

Evidence & Benchmarks

• MOG (35-55) induces EAE in C57BL/6 mice at 50–150 μg/dose, yielding consistent clinical scores and histopathological demyelination (Xu et al., 2025).
• Administration with CFA results in dose-dependent disease onset (typically 9–14 days post-injection), with peak severity at 2–3 weeks (MHC-Class-II-Antigen, 2024).
• MOG (35-55) triggers both T cell (CD4+ Th1/Th17) and B cell autoantibody responses, unlike some alternative EAE inducers (Myelin-Basic-Protein, 2024).
• In vitro, the peptide increases NADPH oxidase and MMP-9 activity, modeling oxidative and matrix-remodeling pathways relevant to CNS injury (Xu et al., 2025).
• PARP7 inhibition in the MOG (35-55) EAE model restores STAT1/STAT2 and mitigates disease, supporting its utility for translational studies of type I interferon pathways (Xu et al., 2025).

This article extends prior benchmarks by integrating new mechanistic findings on the interplay of MOG (35-55) with PARP7-STAT1/STAT2 signaling, as detailed in IGH-1 (2024), and provides detailed protocol guidance beyond the scope of MHC-Class-II-Antigen (2024).

Applications, Limits & Misconceptions

MOG (35-55) is the gold-standard for:

• Inducing EAE in C57BL/6, SJL/J, and HLA-DR2-transgenic mice for relapsing-remitting or chronic MS-like disease.
• Testing immunomodulatory therapies targeting T/B cells, oxidative stress, or interferon signaling.
• Elucidating the molecular mechanisms of neuroinflammation and demyelination.

However, its use is bounded by several factors:

Common Pitfalls or Misconceptions

• Not suitable for all species or strains: Efficacy and disease course can vary outside standard mouse models (e.g., C57BL/6, SJL/J).
• Requires co-administration with CFA: MOG (35-55) alone is insufficient to induce robust EAE; adjuvant is essential.
• Does not replicate all aspects of human MS: The model mimics key features but lacks the full complexity of human disease.
• Solubility and storage impact activity: Improper dissolution (e.g., use of ethanol) or failure to store desiccated at -20°C can compromise efficacy.
• Misinterpretation of weight loss: Weight loss is a general marker of disease severity, but not specific to demyelination.

This article clarifies boundaries of MOG (35-55) utility compared to the scenario-driven solutions described in IGH-1 (2024), emphasizing critical parameters for reproducibility.

Workflow Integration & Parameters

For optimal experimental outcomes:

• Dissolve lyophilized MOG (35-55) in sterile water at 0.50 mg/mL, using gentle warming and ultrasonic bath to enhance solubility (APExBIO).
• Prepare fresh stock solutions or store at -20°C desiccated; avoid repeated freeze/thaw cycles.
• For EAE induction, administer 50–150 μg subcutaneously in emulsion with CFA; co-inject pertussis toxin as per established protocols (MHC-Class-II-Antigen, 2024).
• Monitor mice for onset (typically day 9–14), peak (days 14–21), and remission phases; score disease severity using standardized scales.

The A8306 kit, supplied by APExBIO, is validated for these applications. For advanced workflow guidance, see the strategic framework in Mouse Genotype (2024), which this article updates with the latest evidence on interferon pathway targeting.

Conclusion & Outlook

MOG (35-55) remains the reference standard for EAE induction and MS model development. Its biochemical tractability, robust disease induction, and compatibility with mechanistic immunological studies, including those targeting type I interferon and PARP7-STAT1/2 signaling, underpin its continued relevance (Xu et al., 2025). Ongoing refinement of protocols—anchored by validated products such as those from APExBIO—will further enhance the translational value of this model in neuroinflammation and autoimmune research.